<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Zealand Pharma A/s — News on 6ix</title>
<link>https://6ix.com/company/zealand-pharma-as</link>
<description>Latest news and press releases for Zealand Pharma A/s on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Sun, 19 Apr 2026 20:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/zealand-pharma-as" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836241178dffbe2df142a97.webp</url>
<title>Zealand Pharma A/s</title>
<link>https://6ix.com/company/zealand-pharma-as</link>
</image>
<item>
<title>Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2026</title>
<link>https://6ix.com/company/zealand-pharma-as/news/zealand-pharma-launches-long-term-incentive-programs-for-zealand-pharmas-board-of-directors-corporate-management-and-employees-for-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/zealand-pharma-as/news/zealand-pharma-launches-long-term-incentive-programs-for-zealand-pharmas-board-of-directors-corporate-management-and-employees-for-2026-1</guid>
<pubDate>Sun, 19 Apr 2026 20:00:00 GMT</pubDate>
<description>Company announcement – No. 7 / 2026 Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2026 Copenhagen, Denmark, April 19, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces the implementation of long-term incentive programs for 2026 (the “LTIP”) for the Board of Directors, Corporate Ma</description>
</item>
<item>
<title>Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations</title>
<link>https://6ix.com/company/zealand-pharma-as/news/zealand-pharma-appoints-eric-rojas-as-vice-president-and-head-of-investor-relations-1</link>
<guid isPermaLink="true">https://6ix.com/company/zealand-pharma-as/news/zealand-pharma-appoints-eric-rojas-as-vice-president-and-head-of-investor-relations-1</guid>
<pubDate>Tue, 14 Apr 2026 14:00:00 GMT</pubDate>
<description>Eric Rojas VP, Head of Investor Relations Press release – No. 7 / 2026 Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations Bringing significant experience from Vertex Pharmaceuticals and Shire Copenhagen, Denmark and Boston, Massachusetts, April 14, 2026 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced the appointment of Eric Rojas, Vice President, Investor Relations, effec</description>
</item>
<item>
<title>Total number of shares and voting rights in Zealand Pharma as of March 31, 2026</title>
<link>https://6ix.com/company/zealand-pharma-as/news/total-number-of-shares-and-voting-rights-in-zealand-pharma-as-of-march-31-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/zealand-pharma-as/news/total-number-of-shares-and-voting-rights-in-zealand-pharma-as-of-march-31-2026-1</guid>
<pubDate>Tue, 31 Mar 2026 20:00:00 GMT</pubDate>
<description>Company announcement – No. 6 / 2026 Total number of shares and voting rights in Zealand Pharma as of March 31, 2026 Copenhagen, Denmark, March 31, 2026 – Zealand Pharma A/S (“Zealand Pharma” or "the Company") (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar month during which c</description>
</item>
<item>
<title>Resolutions from Zealand Pharma's Annual General Meeting 2026</title>
<link>https://6ix.com/company/zealand-pharma-as/news/resolutions-from-zealand-pharmas-annual-general-meeting-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/zealand-pharma-as/news/resolutions-from-zealand-pharmas-annual-general-meeting-2026-1</guid>
<pubDate>Thu, 26 Mar 2026 15:57:00 GMT</pubDate>
<description>Company announcement – No. 5 / 2026 Resolutions from Zealand Pharma's Annual General Meeting 2026 Copenhagen, Denmark, March 26, 2026 - Zealand Pharma A/S ("Zealand Pharma" or the “Company”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today held its Annual General Meeting of 2026 as a partly electronic and partly physical general meeting (hybrid meeting). At the Annual General Meeting, all proposals presented to the Annual General Meeti</description>
</item>
<item>
<title>Zealand Pharma Establishes U.S. Research Hub in Cambridge, Massachusetts to Expand Drug Discovery Capabilities and Accelerate Medicine Creation</title>
<link>https://6ix.com/company/zealand-pharma-as/news/zealand-pharma-establishes-us-research-hub-in-cambridge-massachusetts-to-expand-drug-discovery-capabilities-and-accelerate-medicine-creation-1</link>
<guid isPermaLink="true">https://6ix.com/company/zealand-pharma-as/news/zealand-pharma-establishes-us-research-hub-in-cambridge-massachusetts-to-expand-drug-discovery-capabilities-and-accelerate-medicine-creation-1</guid>
<pubDate>Tue, 24 Mar 2026 14:00:00 GMT</pubDate>
<description>Zealand Pharma research hub 35 CambridgePark Drive (4th floor), Cambridge, Massachusetts Press release – No. 6 / 2026 Zealand Pharma Establishes U.S. Research Hub in Cambridge, Massachusetts to Expand Drug Discovery Capabilities and Accelerate Medicine Creation New research hub in Cambridge, Massachusetts, in the greater Boston area, expands global discovery capabilities, combining Zealand Pharma’s more than 25 years of expertise in peptides and metabolic health with Boston’s biotech innovation</description>
</item>
<item>
<title>Zealand Pharma to participate in upcoming investor conferences in March 2026</title>
<link>https://6ix.com/company/zealand-pharma-as/news/zealand-pharma-to-participate-in-upcoming-investor-conferences-in-march-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/zealand-pharma-as/news/zealand-pharma-to-participate-in-upcoming-investor-conferences-in-march-2026-1</guid>
<pubDate>Mon, 09 Mar 2026 16:01:00 GMT</pubDate>
<description>Press release – No. 5 / 2026 Zealand Pharma to participate in upcoming investor conferences in March 2026 Copenhagen, Denmark, March 9, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that the company will participate in the following investor conferences in March 2026. 2026 Jefferies Biotech on the Beach Summit, March 9-11 in Miami Adam Steensberg, President and Chief Executive Officer, will host i</description>
</item>
<item>
<title>Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity</title>
<link>https://6ix.com/company/zealand-pharma-as/news/zealand-pharma-announces-positive-phase-2-results-for-petrelintide-an-amylin-analog-with-potential-to-redefine-the-weight-management-experience-for-people-living-with-overweight-and-obesity-1</link>
<guid isPermaLink="true">https://6ix.com/company/zealand-pharma-as/news/zealand-pharma-announces-positive-phase-2-results-for-petrelintide-an-amylin-analog-with-potential-to-redefine-the-weight-management-experience-for-people-living-with-overweight-and-obesity-1</guid>
<pubDate>Thu, 05 Mar 2026 18:45:00 GMT</pubDate>
<description>Company announcement – No. 3 / 2026 Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity Petrelintide achieved up to 10.7% mean body weight reduction at week 42 (versus 1.7% with placebo) and demonstrated placebo-like tolerabilityAt the maximally effective dose, there were no cases of vomiting and no treatment discontinuations due to gastrointestinal adverse e</description>
</item>
<item>
<title>Zealand Pharma convenes its Annual General Meeting 2026</title>
<link>https://6ix.com/company/zealand-pharma-as/news/zealand-pharma-convenes-its-annual-general-meeting-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/zealand-pharma-as/news/zealand-pharma-convenes-its-annual-general-meeting-2026-1</guid>
<pubDate>Thu, 19 Feb 2026 13:00:00 GMT</pubDate>
<description>Company announcement – No. 2 / 2026 Zealand Pharma convenes its Annual General Meeting 2026 Copenhagen, Denmark, February 19, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, hereby convenes its Annual General Meeting 2026. The Board of Directors of Zealand Pharma A/S hereby convenes the Annual General Meeting of the Company to be held on: Thursday, 26 March 2026 at 03:00 PM (CET)</description>
</item>
<item>
<title>Zealand Pharma Announces Financial Results for the Full Year 2025</title>
<link>https://6ix.com/company/zealand-pharma-as/news/zealand-pharma-announces-financial-results-for-the-full-year-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/zealand-pharma-as/news/zealand-pharma-announces-financial-results-for-the-full-year-2025-1</guid>
<pubDate>Thu, 19 Feb 2026 06:00:00 GMT</pubDate>
<description>Company announcement – No. 1 / 2026 Zealand Pharma Announces Financial Results for the Full Year 2025 2025 marked a quantum leap for Zealand Pharma, with a transformative partnership for petrelintide, strong clinical progress, and organizational readiness, setting the stage for catalyst-rich and defining 2026 Entered a historic and transformative collaboration and license agreement with Roche to unlock the full potential of petrelintide as a future foundational therapy for weight management, aim</description>
</item>
<item>
<title>Zealand Pharma announces positive Phase 1a topline results with Kv1.3 channel blocker ZP9830</title>
<link>https://6ix.com/company/zealand-pharma-as/news/zealand-pharma-announces-positive-phase-063000144</link>
<guid isPermaLink="true">https://6ix.com/company/zealand-pharma-as/news/zealand-pharma-announces-positive-phase-063000144</guid>
<pubDate>Wed, 18 Feb 2026 06:30:00 GMT</pubDate>
<description>Press release – No. 4 / 2026 Zealand Pharma announces positive Phase 1a topline results with Kv1.3 channel blocker ZP9830 Single doses of ZP9830 were well tolerated, with no serious or severe adverse events or dose-limiting safety findings observed at any dose levelZP9830 exhibited a pharmacokinetic profile in line with predictions based on preclinical data, and exploratory pharmacodynamic biomarkers showed robust, dose-dependent activity consistent with Kv1.3 target engagementZP9830 is a highly</description>
</item>
<item>
<title>Zealand Pharma conference call on February 19 at 2pm CET (8am ET) to present full year 2025 financial results</title>
<link>https://6ix.com/company/zealand-pharma-as/news/zealand-pharma-conference-call-february-160100564</link>
<guid isPermaLink="true">https://6ix.com/company/zealand-pharma-as/news/zealand-pharma-conference-call-february-160100564</guid>
<pubDate>Thu, 12 Feb 2026 16:01:00 GMT</pubDate>
<description>Press Release – No. 3 / 2026 Zealand Pharma conference call on February 19 at 2pm CET (8am ET) to present full year 2025 financial results Copenhagen, Denmark, February 12, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, announced that it will host a conference call on February 19, 2026, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the full year of 2025. Participating in the call</description>
</item>
<item>
<title>Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy</title>
<link>https://6ix.com/company/zealand-pharma-as/news/zealand-pharma-enters-agreement-dcai-070000884</link>
<guid isPermaLink="true">https://6ix.com/company/zealand-pharma-as/news/zealand-pharma-enters-agreement-dcai-070000884</guid>
<pubDate>Fri, 09 Jan 2026 07:00:00 GMT</pubDate>
<description>Press release – No. 2 / 2026 Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy Access to Gefion, Denmark’s flagship AI supercomputer, gives Zealand Pharma access to unprecedented computational power, enabling large-scale modeling, prediction, and optimization of drug candidatesAgreement will support Zealand Pharma’s Metabolic Frontier 2030 strategy to deliver five launches, +10 clinical pipeline prog</description>
</item>
<item>
<title>Zealand Pharma to present at the J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/zealand-pharma-as/news/zealand-pharma-present-j-p-160500401</link>
<guid isPermaLink="true">https://6ix.com/company/zealand-pharma-as/news/zealand-pharma-present-j-p-160500401</guid>
<pubDate>Mon, 05 Jan 2026 16:05:00 GMT</pubDate>
<description>Press release – No. 1 / 2026 Zealand Pharma to present at the J.P. Morgan Healthcare Conference Copenhagen, Denmark, January 5, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that the Company will participate in the 44th J.P. Morgan Healthcare Conference on January 12-15, 2026 in San Francisco, California. Adam Steensberg, President and Chief Executive Officer, w</description>
</item>
<item>
<title>Total number of shares and voting rights in Zealand Pharma as of December 31, 2025</title>
<link>https://6ix.com/company/zealand-pharma-as/news/total-number-shares-voting-rights-160500679</link>
<guid isPermaLink="true">https://6ix.com/company/zealand-pharma-as/news/total-number-shares-voting-rights-160500679</guid>
<pubDate>Wed, 31 Dec 2025 16:05:00 GMT</pubDate>
<description>Company announcement – No. 27 / 2025 Total number of shares and voting rights in Zealand Pharma as of December 31, 2025 Copenhagen, Denmark, December 31, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar month during</description>
</item>
<item>
<title>Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons</title>
<link>https://6ix.com/company/zealand-pharma-as/news/transactions-zealand-pharma-shares-related-210000321</link>
<guid isPermaLink="true">https://6ix.com/company/zealand-pharma-as/news/transactions-zealand-pharma-shares-related-210000321</guid>
<pubDate>Fri, 19 Dec 2025 21:00:00 GMT</pubDate>
<description>Company announcement – No. 26 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, December 19, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology transforming the future of metabolic health, has received information on transactions in Zealand Pharma's shares or related securities conducted by persons disch</description>
</item>
<item>
<title>Zealand Pharma increases its share capital as a result of the exercise of employee warrants</title>
<link>https://6ix.com/company/zealand-pharma-as/news/zealand-pharma-increases-share-capital-210000487</link>
<guid isPermaLink="true">https://6ix.com/company/zealand-pharma-as/news/zealand-pharma-increases-share-capital-210000487</guid>
<pubDate>Thu, 11 Dec 2025 21:00:00 GMT</pubDate>
<description>Company announcement – No. 25 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, December 11, 2025 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78),), a biotechnology company transforming the future of metabolic health, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 150,317 divided into 150,317 new shares with a nominal value of DKK 1 each. The capita</description>
</item>
<item>
<title>Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health</title>
<link>https://6ix.com/company/zealand-pharma-as/news/zealand-pharma-outlines-metabolic-frontier-060500628</link>
<guid isPermaLink="true">https://6ix.com/company/zealand-pharma-as/news/zealand-pharma-outlines-metabolic-frontier-060500628</guid>
<pubDate>Thu, 11 Dec 2025 06:05:00 GMT</pubDate>
<description>Press release – No. 19 / 2025 Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health Zealand Pharma targets five launches, +10 clinical pipeline programs, and industry-leading cycle times from idea to clinic by 2030Catalyst-rich 2026 with multiple clinical readouts, including Phase 2 data with petrelintide in Q1 2026 and Phase 3 obesity data with survodutide throughout 2026New research site in Boston to combine our +25-yea</description>
</item>
<item>
<title>Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases</title>
<link>https://6ix.com/company/zealand-pharma-as/news/zealand-pharma-otr-therapeutics-enter-060000349</link>
<guid isPermaLink="true">https://6ix.com/company/zealand-pharma-as/news/zealand-pharma-otr-therapeutics-enter-060000349</guid>
<pubDate>Thu, 11 Dec 2025 06:00:00 GMT</pubDate>
<description>Press release – No. 18 / 2025 Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases Collaboration will combine Zealand Pharma’s expertise in obesity and metabolic health with OTR Therapeutics’ proprietary oral small-molecule platform and strong drug discovery capabilities, to discover and develop novel therapeutics for multiple targets in metabolic diseasesOTR Therapeutics will receive an initial</description>
</item>
<item>
<title>REMINDER: Zealand Pharma’s Capital Markets Day on December 11, 2025</title>
<link>https://6ix.com/company/zealand-pharma-as/news/reminder-zealand-pharma-capital-markets-160000738</link>
<guid isPermaLink="true">https://6ix.com/company/zealand-pharma-as/news/reminder-zealand-pharma-capital-markets-160000738</guid>
<pubDate>Mon, 01 Dec 2025 16:00:00 GMT</pubDate>
<description>Press release – No. 17 / 2025 REMINDER: Zealand Pharma’s Capital Markets Day on December 11, 2025 Copenhagen, Denmark, December 1, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, is hosting a Capital Markets Day in London on December 11, 2025, featuring presentations from management and external experts in obesity and metabolism. Time: December 11, 2025, from 1.00-5.30pm GMT (2.00</description>
</item>
<item>
<title>Zealand Pharma Announces Financial Results for the First Nine Months of 2025</title>
<link>https://6ix.com/company/zealand-pharma-as/news/zealand-pharma-announces-financial-results-060000985</link>
<guid isPermaLink="true">https://6ix.com/company/zealand-pharma-as/news/zealand-pharma-announces-financial-results-060000985</guid>
<pubDate>Thu, 13 Nov 2025 06:00:00 GMT</pubDate>
<description>Company announcement – No. 23 / 2025 Zealand Pharma Announces Financial Results for the First Nine Months of 2025With petrelintide advancing at full speed and topline data rapidly approaching for both petrelintide and survodutide, upcoming Capital Markets Day will set the stage for a catalyst-rich 2026. Achieved key milestone in the petrelintide Phase 2 ZUPREME-1 trial in people with overweight and obesity, with the last participant completing the 28-week primary endpoint visit, paving the way f</description>
</item>
</channel>
</rss>